Univariate analysis performed on patients at diagnosis
. | OS . | . | . | PFS . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | HR . | 95% CI . | P . | HR . | 95% CI . | P . | ||||
| Age | 0.99 | 0.95-1.03 | NS | 1.00 | 0.97-1.03 | NS | ||||
| Female | 0.77 | 0.41-1.48 | NS | 1.07 | 0.60-1.89 | NS | ||||
| Salmon and Durie stage III | 1.01 | 0.50-2.03 | NS | 1.41 | 0.72-2.76 | NS | ||||
| β2-microglobulin* | 1.08 | 1.00-1.16 | .06 | 1.14 | 1.05-1.24 | < .005 | ||||
| Creatinine level | 0.89 | 0.71-1.11 | NS | 0.99 | 0.83-1.18 | NS | ||||
| Hb level | 0.92 | 0.79-1.08 | NS | 0.83 | 0.72-0.96 | NS | ||||
| Bone lesions, 0 | 0.77 | 0.34-1.74 | NS | 0.93 | 0.46-1.86 | NS | ||||
| BM PCs, % | 1.00 | 0.99-1.02 | NS | 1.01 | 0.99-1.02 | NS | ||||
| COX-2 positivity | 1.89 | 1.01-3.60 | < .05 | 4.04 | 2.20-7.40 | < .001 | ||||
. | OS . | . | . | PFS . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | HR . | 95% CI . | P . | HR . | 95% CI . | P . | ||||
| Age | 0.99 | 0.95-1.03 | NS | 1.00 | 0.97-1.03 | NS | ||||
| Female | 0.77 | 0.41-1.48 | NS | 1.07 | 0.60-1.89 | NS | ||||
| Salmon and Durie stage III | 1.01 | 0.50-2.03 | NS | 1.41 | 0.72-2.76 | NS | ||||
| β2-microglobulin* | 1.08 | 1.00-1.16 | .06 | 1.14 | 1.05-1.24 | < .005 | ||||
| Creatinine level | 0.89 | 0.71-1.11 | NS | 0.99 | 0.83-1.18 | NS | ||||
| Hb level | 0.92 | 0.79-1.08 | NS | 0.83 | 0.72-0.96 | NS | ||||
| Bone lesions, 0 | 0.77 | 0.34-1.74 | NS | 0.93 | 0.46-1.86 | NS | ||||
| BM PCs, % | 1.00 | 0.99-1.02 | NS | 1.01 | 0.99-1.02 | NS | ||||
| COX-2 positivity | 1.89 | 1.01-3.60 | < .05 | 4.04 | 2.20-7.40 | < .001 | ||||
OS indicates overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; Hb, hemoglobin; BM, bone marrow; PCs, plasma cells.
β2-microglobulin was available in 77 patients.